Brief: Aurinia Pharmaceuticals To Acquire Kezar Life Sciences For $6.955 In Cash Per Share Plus A Contingent Value Right
30/03/2026 14:59
March 30 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O: AURINIA PHARMACEUTICALS TO ACQUIRE KEZAR LIFE SCIENCES FOR $6.955 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHT AURINIA PHARMACEUTICALS TO ACQUIRE KEZAR LIFE SCIENCES FOR $6.955 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHT AURINIA PHARMACEUTICALS INC - CVR INCLUDES PAYMENTS FROM ZETOMIPZOMIB, EVEREST, ENODIA, AND NET CASH OVER $50 MILLION Source text: ID:nBwLVLvLa Further company coverage: AUPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death